A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis

ar2131 ARJ Research article A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for autoantibody production in rheumatoid arthritis Gourraud Pierre-Antoine Dieudé Philippe Boyer Jean-Frédéric Nogueira Leonor Cambon-Thomsen Anne Mazières Bernard Cornélis François Serre Guy Cantagrel Alain Constantin Arnaud constant@cict.fr

Service d'Epidémiologie CHU Toulouse, INSERM, U558, Université Paul Sabatier Toulouse III, Faculté de Médecine, 37 allées Jules Guesde, Toulouse Cedex 7, 31073, France

Service de Rhumatologie, CHU Bichat Claude-Bernard, 46 rue Henri Huchard, Paris, 75018, France

GRCB40, UFR Sciences Médicales Rangueil, 1 avenue du Professeur Jean Poulhès, Toulouse Cedex 9, 31059, France

Service de Rhumatologie, CHU Toulouse Rangueil, 1 avenue du Professeur Jean Poulhès, Toulouse Cedex 9, 31059, France

Laboratoire de Biologie Cellulaire et Cytologie, CHU Toulouse Purpan, Place du Docteur Baylac, Toulouse cedex 9, 31059, France

GenHotel, Genopole, 2 rue Gaston Crémieux, Evry Cedex, 91057, France

INSERM, U558, Faculté de Médecine, 37 allées Jules Guesde, Toulouse Cedex 7, 31073, France

Arthritis Research & Therapy 1478-6354 2007 9 2 R27 http://arthritis-research.com/content/9/2/R27 17328818 10.1186/ar2131 27 11 2006 2 2 2007 5 3 2007 12 3 2007 12 3 2007 2007 Gourraud et al., licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

The HLA-DRB1 gene was reported to be associated with anticitrullinated protein/peptide autoantibody (ACPA) production in rheumatoid arthritis (RA) patients. A new classification of HLA-DRB1 alleles, reshaping the shared epitope (SE) hypothesis, was recently found relevant in terms of RA susceptibility and structural severity.

We investigated the relevance of this new classification of HLA-DRB1 SE⁺alleles in terms of rheumatoid factor (RF) and ACPA production in a sample of French RA patients.

We studied 160 early RA patients included in a prospective longitudinal cohort of French Caucasian patients with recent-onset arthritis. RF, anticyclic citrullinated peptide 2 (anti-CCP2) and antideiminated human fibrinogen autoantibodies (AhFibA) were assessed in all patients at inclusion. The HLA-DRB1 gene was typed by PCR-sequence specific oligonucleotides probes (PCR-SSOP), and SE+ alleles were classified into four groups (S1, S2, S3P, S3D) according to the new classification.

The new classification of HLA-DRB1 SE+ alleles distinguishes predisposing and protective alleles for RF, anti-CCP2 or AhFibA production. The presence of S2 or S3P alleles is associated with both RF, anti-CCP2 or AhFibA positivity, whereas the presence of S3D or S1 alleles appears to be protective for RF, anti-CCP2 or AhFibA positivity.

The new classification of HLA-DRB1 SE⁺alleles is relevant in terms of autoantibody production in early RA patients by differentiating predisposing and protective alleles for RF or ACPA production.

Introduction

Since early rheumatoid arthritis (RA) is often indistinguishable from other inflammatory joint diseases, recent-onset inflammatory synovitis poses a diagnostic and prognostic challenge to rheumatologists 1. The identification and validation of immunologic and genetic markers with strong diagnostic and prognostic value in early RA may help rheumatologists to meet this challenge 2.

Among immunologic markers, anticitrullinated protein/peptide antibodies (ACPAs) constitute relevant tools in the diagnosis and prognosis of early RA. Citrulline is a nonstandard amino acid, generated by post-translational modifications of several proteins by deimination of arginine residues by peptidylarginine deiminases 34. The citrulline moiety is the true determinant in proteins recognized by antiperinuclear factor 5, antikeratin antibodies 6, antifilaggrin antibodies 7, anticyclic citrullinated peptide (anti-CCP) antibodies 8 and anti-deiminated human fibrinogen autoantibodies (AhFibA) 91011. ACPAs may be detected in healthy individuals, years before the onset of symptoms of RA 1213, and may predict progression to persistent erosive arthritis or to RA in patients with undifferentiated arthritis 141516. ACPAs are as sensitive as, and more specific than, rheumatoid factor (RF) for early RA diagnosis 171819. Furthermore, ACPAs represent a prognostic factor for erosive disease in early RA 2021222324.

Among genetic markers, the HLA-DRB1 gene has been clearly involved in the pathogenesis of RA 2526. The association between HLA-Dw4 and RA was first reported in 1976 27. The development of HLA-DRB1 genotyping led to the demonstration that different HLA-DR4 alleles were not equally associated with RA and that several non-DR4 HLA–DRB1 alleles were also associated with the disease. The shared epitope (SE) hypothesis, first proposed in 1987, represents an approach to understand the molecular genetics of susceptibility to RA. The SE hypothesis assumes that HLA-DRB1 alleles encoding a highly conserved amino acid sequence, known as the SE – which is characterized by the RAA pattern at positions 72–74 of the third hypervariable region of different HLA-DRβ₁chains – are associated with susceptibility to RA 28. HLA-DRB1 alleles encoding the SE were then associated with structural severity of RA 29 and have been more recently associated with production of ACPAs 91224303132.

As was done in previous attempts 3334, du Montcel and colleagues recently introduced a new classification of HLA-DRB1 alleles that reconsiders the SE hypothesis 35. In terms of susceptibility to RA, this new classification suggests that the risk of developing RA depends on whether the RAA sequence occupies positions 72–74 but the risk is modulated by the amino acids at position 71 (K confers the higher risk, R an intermediate risk, A and E a lower risk) and at position 70 (Q or R confers a higher risk than D) 353637 complexifying the classical SE epitope classification based on the presence of RAA in positions 72–74. In terms of structural severity of RA, this new classification allowed the differentiation of predisposing or protective alleles (two effects) – respectively characterized by the DRRAA or by the DERAA amino acid pattern at positions 70–74 36 – which was not possible using the classical SE epitope classification based on the only presence of RAA in positions 72–74.

In the present study, we investigated the relevance of this new classification of HLA-DRB1 alleles in terms of RF and ACPA production in a cohort of French Caucasian patients with early RA. Interestingly, the new classification of HLA-DRB1 alleles allows the differentiation between predisposing and protective alleles for autoantibody production.

Materials and methods

Patients

One hundred and sixty Caucasian outpatients were selected from the Rangueil Midi-Pyrénées cohort, which involved patients with early arthritis who attended the Rangueil Hospital Department of Rheumatology between November 1992 and December 1997, according to the following criteria: the American College of Rheumatology 1987 criteria for RA 38, disease duration <1 year from the first clinical manifestation of RA, and age over 16 years.

Each individual included in the Rangueil Midi-Pyrénées cohort signed an informed consent form. The protocol was initially approved by the Committee for the Protection of Persons Participating in Biomedical Research (French law 88–1138 December 20, 1988).

Detection of RF and ACPAs

Blood samples were collected at baseline, immediately centrifuged and stored at -80°C until assayed. RF was quantified by nephelometry according to the manufacturer's recommendations (RF Reagent, IMMAGE immunochemistry system; Beckman Coulter, Inc., Fullerton, CA, USA). Anti-CCP2 antibodies were detected by ELISA according to the instructions of the manufacturer (IMMUNOSCAN RA; Euro-Diagnostica, Arnhem, The Netherlands). AhFibA were detected with a recently developed inhouse ELISA, using in vitro deiminated human fibrinogen as immunosorbent 910. The cut-off points of the two ELISAs were previously set so they reached the same diagnostic specificity of 98.5%.

HLA-DRB1 genotyping and allele classification

Genomic DNA was extracted from ethylenediamine tetraacetic acid anticoagulated peripheral blood, using a standard proteinase K digestion and phenol/chloroform extraction method, in all patients at the time of inclusion. HLA-DRB1 typing and subtyping were performed by a PCR-based method, using a panel of sequence-specific oligonucleotide probes 36.

HLA-DRB1 alleles were pooled according to the new classification proposed by du Montcel and colleagues 3536. Briefly, the HLA-DRB1 alleles were first divided into two groups according to the presence or absence of the RAA sequence at positions 72–74 and were denoted S and X alleles, respectively. The S alleles were subsequently divided into four groups according to the amino acid at position 71: an alanine (A), a glutamic acid (E), a lysine (K), or an arginine (R). Different groups were thus defined in the new classification: S1 for ARAA and ERAA, S2 for KRAA, S3 for RRAA, and X for all non-RAA patterns. Since an aspartic acid (D) at position 70 was reported to be protective against RA susceptibility in comparison with a glutamine (Q) or an arginine (R) at the same position 39, two additional groups were defined: S3D for DRRAA, and S3P for QRRAA or RRRAA 3536 (Table 1).

Table 1

HLA–DRB1 amino acid sequence for alleles observed among rheumatoid arthritis patients and their classification according to du Montcel and colleagues

HLA-DRB1 allele

Amino acid position

Classification of du Montcel and colleagues

HLA-DRB1*0101

S3P

HLA-DRB1*0102

S3P

HLA-DRB1*0103

HLA-DRB1*03

HLA-DRB1*0401

HLA-DRB1*0402

HLA-DRB1*0403

HLA-DRB1*0404

S3P

HLA-DRB1*0405

S3P

HLA-DRB1*0407

HLA-DRB1*0408

S3P

HLA-DRB1*0411

HLA-DRB1*07

HLA-DRB1*08

HLA-DRB1*0901

HLA-DRB1*1001

S3P

HLA-DRB1*1101

S3D

HLA-DRB1*1102

HLA-DRB1*1103

HLA-DRB1*1104

S3D

HLA-DRB1*12

S3D

HLA-DRB1*1301

HLA-DRB1*1302

HLA-DRB1*1303

HLA-DRB1*1323

HLA-DRB1*1401

HLA-DRB1*1402

S3P

HLA-DRB1*1404

HLA-DRB1*15

HLA-DRB1*16

S3D

In the du Montcel and colleagues classification [35], the HLA–DRB1 alleles were first divided into two groups according to the presence or absence of the RAA sequence at positions 72–74, which denote S and X alleles (respectively shared epitope and nonshared epitope alleles). The S alleles were subsequently divided into four groups according to the two first amino acids at positions 70 and 71 (boldface): S1 for ARAA and ERAA, S2 for KRAA, S3 for RRAA (divided into S3P for QRRAA and S3D for DRRAA according to position 70), and X for all non-RAA motifs. The conventional classification of the amino acids was used, here divided into three biochemical subgroups, as follows: group 1 = G for glycine, A for alanine, V for valine, L for leucine (aliphatic amino acids (nonpolar hydrophobic)); group 2 = K for lysine, R for arginine (basic amino acids (polar and positively charged)); group 3 = E for glutamic acid, Q for glutamine (the amide corresponding to E), D for aspartic acid, and N for asparagine (the amide corresponding to D) (acidic amino acids and corresponding amides are very hydrophilic; acidic amino acids are polar and negatively charged at physiologic pH, amides are polar and uncharged, and not ionizable) [36].

Statistical analysis

Agreements with Hardy–Weinberg equilibrium were tested using Pearson's chi-square test and Fischer's exact test when relevant. The association between the HLA-DRB1 gene polymorphism and RF or ACPAs was tested by comparing (by the chi-square test or the exact Fisher test when relevant) the distribution of positive or negative patients for RF or anti-CCP2 antibodies or AhFibA among carriers and noncarriers for each of the four groups of HLA-DRB1 alleles encoding the SE, defined according to the new classification of HLA-DRB1 alleles (S1D, S2D, S3P, S3D). Odds and odds ratios (95% confidence intervals) were also calculated. The dose effect was investigated for alleles positively or negatively associated with immunological markers using tests for the trend of the log odds.

Statistical analyses were performed using Stata Statistical Software (release 9.1 SE; Stata Corporation, College Station, TX, USA). All P values were two-sided, and P < 0.05 was considered statistically significant after correcting when relevant for multiple testing according to the Benjamini–Yekutieli 2001 method.

Results

Demographic and immunologic characteristics of RA patients

The main baseline demographic and immunologic characteristics of the 160 patients with early RA included in the present study were the following: 120 women (75%) and 40 men (25%); mean (± standard deviation) age, 50.31 (± 14.03) years; mean (± standard deviation) disease duration, 0.55 (± 0.02) years; number (%) RF-positive, 110/160 (68.75%); number (%) anti-CCP2 antibody-positive, 110/160 (68.75%); and number (%) AhFibA-positive, 108/160 (67.25%).

Allele frequencies for HLA-DRB1 polymorphisms

The frequencies of HLA-DRB1 alleles, classified into five groups according to the new classification, were as follows: S1, 59/320 (18.4%); S2, 65/320 (20.3%); S3D, 42/320 (13.3%); S3P, 89/320 (27.81%); and X, 65/320 (20.31). No departures from Hardy–Weinberg equilibrium were found for HLA-DRB1 alleles classified into the five groups (P = 0.7171; 10 degrees of freedom).

Relationship between HLA-DRB1 allele carrier status and RF status

Table 2 presents the status for RF among patients carrying the different HLA-DRB1 alleles encoding the SE classified into four groups according to the new classification. On the one hand, S2 carriers had a higher frequency of RF in comparison with noncarriers (odds ratio > 1 and P < 0.05). On the other hand, S3D and S1 carriers had a lower frequency of RF in comparison with noncarriers (odds ratio < 1 and P < 0.05).

Table 2

Relationship between HLA-DRB1 allele carrier status and rheumatoid factor status in French patients with early rheumatoid arthritis

Carrier status

Odds ratio (95% confidence interval)

P for trend

Yes

S1 carrier

Rheumatoid factor-positive

31 (55.4)

79 (75.9)

0.39 (0.19–0.83)

0.0118

0.0051*

Rheumatoid factor-negative

25 (44.6)

25 (24.0)

S2 carrier

Rheumatoid factor-positive

49 (83.1)

61 (60.4)

3.21 (1.39–7.9)

0.0028*

0.0049*

Rheumatoid factor-negative

10 (16.9)

40 (39.6)

S3P carrier

Rheumatoid factor-positive

57 (74.0)

53 (63.9)

1.61 (0.78–3.38)

0.1766

0.4478

Rheumatoid factor-negative

20 (26.0)

30 (36.1)

S3D carrier

Rheumatoid factor-positive

19 (51.4)

91 (74.0)

0.37 (0.16–0.86)

0.0145

0.0209

Rheumatoid factor-negative

18 (48.6)

32 (26.0)

Data presented as n (%). Status for rheumatoid factor among 160 patients with early rheumatoid arthritis, carrying the different HLA-DRB1 alleles encoding the shared epitope classified into four groups according to the new classification. Odds ratios, 95% alpha-risk confidence interval and P value for exact Fisher test. The dose effect was investigated for alleles positively or negatively associated with immunological markers using tests for trend of the log odds. *Significant after correcting for multiple testing according to the Benjamini–Yekutieli 2001 method at an overall critical P value of 5%.

These results support the hypothesis of an association between HLA-DRB1 gene polymorphisms and RF, and the results point out the interest of the new classification of HLA-DRB1 alleles in order to differentiate predisposing and protective alleles for RF production in early RA.

Relationship between HLA-DRB1 allele carrier status and anticitrullinated protein/peptide autoantibody status

Table 3 presents the status for anti-CCP2 antibodies or AhFibA among patients carrying the different HLA-DRB1 alleles encoding the SE classified into four groups according to the new classification. On the one hand, S2 and S3P carriers had a higher frequency of anti-CCP2 antibodies or AhFibA in comparison with noncarriers (odds ratio > 1 and P < 0.05). On the other hand, S3D and S1 carriers had a lower frequency of anti-CCP2 antibodies or AhFibA in comparison with noncarriers (odds ratio < 1 and P < 0.05).

Table 3

Relationship between HLA-DRB1 allele carrier status and anticitrullinated protein/peptide autoantibody status in French patients with early rheumatoid arthritis

Carrier status

Odds ratio (95% confidence interval)

P for trend

Yes

S1 carrier

CCP2-positive

32 (57.1)

78 (75.0)

0.44 (0.21–0.94)

0.0312

0.0134

CCP2-negative

24 (42.9)

26 (25.0)

AhFibA-positive

31 (55.4)

77 (74.0)

0.43 (0.21–0.91)

0.0213

0.0113

AhFibA-negative

25 (44.6)

27 (26.0)

CCP2-positive

CCP2-negative

49 (83.1)

61 (60.4)

3.21 (1.39–7.9)

0.0028*

0.0049*

AhFibA-positive

10 (16.9)

40 (39.6)

AhFibA-negative

50 (84.8)

58 (57.4)

4.12 (1.75–10.49)

0.0004*

0.0003*

CCP2-positive

9 (15.2)

43 (42.6)

S3P carrier

CCP2-positive

61 (79.2)

49 (59.0)

2.65 (1.24–5.74)

0.0066*

0.0014*

CCP2-negative

16 (20.8)

34 (41.0)

AhFibA-positive

61 (79.2)

47 (56.6)

2.92 (1.38–6.32)

0.0025*

0.0035*

AhFibA-negative

16 (20.8)

36 (43.4)

S3D carrier

CCP2-positive

17 (45.9)

93 (75.6)

0.27 (0.12–0.63)

0.0011*

0.0009*

CCP2-negative

20 (54.1)

30 (24.4)

AhFibA-positive

19 (51.4)

89 (72.4)

0.4 (0.18–0.93)

0.0266

0.0145

AhFibA-negative

18 (48.6)

34 (27.6)

Data presented as n (%). Status for anticyclic citrullinated peptides (anti-CCP2) antibodies or antideiminated human fibrinogen autoantibodies (AhFibA) among 160 patients with early rheumatoid arthritis, carrying the different HLA-DRB1 alleles encoding the shared epitope classified into four groups according to the new classification. Odds ratios, 95% alpha-risk confidence interval and P value for exact Fisher test. The dose effect was investigated for alleles positively or negatively associated with immunological markers using tests for trend of the log odds. *Significant after correcting for multiple testing according to the Benjamini–Yekutieli 2001 method at an overall critical P value of 5%.

The interest of the new classification is that both predisposing and protective alleles for the production of ACPA are found. The effects remain significant after correction for multiple testing using the Benjamini–Yekutieli 2001 procedure implemented in STATA 9.0 (State Corporation), which corrects for an overall false discovery rate (5% here) (see Table 3). In the present analysis based on carrier status, a potential bias may be introduced by the presence of an adverse effect allele in the control group. In the analysis of the S2 effect, for example, the association may be overestimated by the presence of S3D carriers in the control group (noncarrier of S2). The effect of S2 may similarly be underestimated by the presence of S3P carriers. After controlling for the adverse effect of S3D and S1 in the analysis of S2, the association with the positivity of Ahfiba remains significant (P < 0.05). After controlling for the adverse effect of S2 and S3P in the analysis of S3D, the association with negativity of anti-CCP2 remained significant.

These results support the hypothesis of an association between HLA-DRB1 gene polymorphisms and ACPAs, and point out the interest of the new classification of HLA-DRB1 alleles in order to differentiate predisposing and protective alleles for ACPA production in early RA.

Discussion

The results of the present study confirm previous evidence of an association between HLA-DRB1 gene polymorphisms and RF or ACPAs in RA. Furthermore, the results point out the interest of the new classification of HLA-DRB1 alleles in order to differentiate predisposing and protective alleles for autoantibody production in early RA.

The results of the present study confirm previous evidence of an association between HLA-DRB1 gene polymorphisms and autoantibody production in RA. We found a positive association between carriers of HLA-DRB1*SE⁺alleles (HLA-DRB1*0401, HLA-DRB1*0404, HLA-DRB1*0405, HLA-DRB1*0408, HLA-DRB1*1001) and RF or ACPA production, while we did not find any negative association between carriers of HLADRB1*SE^-alleles and RF or ACPA production (data not shown). An association between HLA-DRB1*04 or HLA-DRB1*SE⁺alleles and RF has been reported in some studies 123040 but rejected in others 123241. An association between HLA-DRB1*01, HLA-DRB1*04 or HLA-DRB1*SE⁺alleles and ACPAs was more constantly reported in European or North American RA patients 9122430324042434445. Since the presence of RF was strongly correlated with that of ACPAs in most of these studies, several groups investigated whether these associations between HLA-DRB1 gene polymorphisms and RF or ACPAs were independent. These studies showed that the association between HLA-DRB1*SE⁺alleles and ACPAs is constantly stronger than the association between HLA-DRB1*SE⁺alleles and RF. Furthermore, they suggested that the association between HLA-DRB1*SE⁺alleles and ACPAs is independent of the RF status, leading to the conclusion that HLA-DRB1*SE⁺alleles are primarily associated with the presence of ACPAs, but not with the presence of RF 243241.

The results of the present study indicate the interest of the new classification of HLA-DRB1 alleles to differentiate predisposing and protective alleles for autoantibody production in early RA. This new classification, which is based on an initial split of HLA-DRB1 alleles into two groups according to the presence (S alleles) or absence (X alleles) of the RAA sequence at positions 72–74, subsequently divides S alleles into four groups according to the amino acids at positions 71 and 70. Most of the previous studies, based on the common classification, identified HLA-DRB1*101, HLA-DRB1*0401, HLA-DRB1*404 and HLA-DRB1*1001 as predisposing alleles for ACPA production in RA, with a significant dose effect in patients carrying two of these predisposing alleles 9123244. Only a few association studies reported an HLA-DRB1 allelic protective effect for ACPA production in RA. In these studies, HLA-DRB1*03 was associated with ACPA-negative RA and decreased titers of ACPAs, even in the presence of an SE allele 3245. In the new classification of HLA-DB1 allelles, HLA-DRB1*03 is not taken into account separately since it is classified into the X group of alleles, which do not encode the SE sequence. In the present study, complementary analysis did not show any association between HLA-DRB1*03 carrier status and RF or ACPA production (data not shown). The use of the classification by du Montcel and colleagues suggests a risk hierarchy in ACPA production in early RA patients: the S2 (KRAA at positions 71–74) and S3P (QRRAA or RRRAA at positions 70–74) alleles conferring predisposition, while the S1 (ARAA or ERAA at positions 71–74) and S3D (DRRAA at positions 70–74) alleles confer protection, in comparison with X (non-RAA patterns at positions 72–74).

The use of the new classification of HLA-DRB1 alleles proposed by du Montcel and colleagues seems to provide different pictures of the relative contribution of the HLA-DRB1 locus to RA pathogenesis. This relative contribution is not restricted to ACPA production, but also includes risk hierarchy for RA susceptibility and structural severity 353637.

Trying to understand the findings of genetic association/linkage studies in complex multifactorial diseases, such as RA, in light of the amino acid alignment of a protein encoded by a candidate gene remains a challenging task. In fact, the interactions between HLA-DRB1 molecules and citrullinated peptides may impact RA pathogenesis in several ways. For example, a previous study conducted in DR4-IE transgenic mice demonstrated that the conversion of arginine to citrulline at the peptide side-chain position interacting with the SE significantly increases peptide–MHC affinity and leads to the activation of CD4⁺T cells, suggesting that HLA-DRB1 alleles encoding the SE could initiate an autoimmune response to citrullinated self-antigens 46.

Conclusion

Although no formal conclusions on causality can be drawn from the present association study, our findings indicate the interest of this new classification of HLA-DRB1 alleles in order to differentiate predisposing and protective alleles for autoantibody production in RA.

Abbreviations

ACPA = anticitrullinated protein/peptide autoantibody; AhFibA = antideiminated human fibrinogen autoantibodies; anti-CCP = anticyclic citrullinated peptide; ELISA = enzyme-linked immunosorbent assay; HLA = human leukocyte antigen; MHC = minor histocompatibility complex, PCR = polymerase chain reaction; RA = rheumatoid arthritis; RF = rheumatoid factor; SE = shared epitope.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

P-AG and ACo took the leadership of the study in both clinical immunological and statistical aspects. FC and PD contributed specifically to the genotyping. GS and LN were specifically in charge of the autoantibody study. AC-T contributed to the statistical analysis. BM, ACa and J-FB contributed through the assessment of the RMP cohort.

Acknowledgements

The authors acknowledge the contribution of Delphine Nigon as a clinical research data manager as well as the help of the Computational platform for Clinical research and Analysis in Epidemiology & Public Health Midi-Pyrenees (TIERSMIP).

Evaluating patients with arthritis of recent onset: studies in pathogenesis and prognosis El-Gabalawy HS Duray P Goldbach-Mansky R JAMA 2000 284 2368 2373 10.1001/jama.284.18.2368 11066188 The diagnosis and prognosis of early arthritis: rationale for new prognostic criteria Scott DL Arthritis Rheum 2002 46 286 290 10.1002/art.10134 11840430 The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues Girbal-Neuhauser E Durieux JJ Arnaud M Dalbon P Sebbag M Vincent C Simon M Senshu T Masson-Bessiere C Jolivet-Reynaud C J Immunol 1999 162 585 594 9886436 Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies Schellekens GA de Jong BA van den Hoogen FH van de Putte LB van Venrooij WJ J Clin Invest 1998 101 273 281 508564 9421490 A new serum factor in patients with rheumatoid arthritis; the antiperinuclear factor Nienhuis RL Mandema E Ann Rheum Dis 1964 23 302 305 1030930 14178016 Association of HLA-DR4/Dw4 and DR2/Dw2 with radiologic changes in a prospective study of patients with rheumatoid arthritis. Preferential relationship with HLA-Dw rather than HLA-DR specificities Young A Jaraquemada D Awad J Festenstein H Corbett M Hay FC Roitt IM Arthritis Rheum 1984 27 20 25 10.1002/art.1780270104 6197976 The cytokeratin filament-aggregating protein filaggrin is the target of the so-called "antikeratin antibodies,' autoantibodies specific for rheumatoid arthritis Simon M Girbal E Sebbag M Gomes-Daudrix V Vincent C Salama G Serre G J Clin Invest 1993 92 1387 1393 288281 7690781 The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide Schellekens GA Visser H de Jong BA van den Hoogen FH Hazes JM Breedveld FC van Venrooij WJ Arthritis Rheum 2000 43 155 163 10.1002/1529-0131(200001)43:1<155::AID-ANR20>3.0.CO;2-3 10643712 Influence of HLA-DR genes on the production of rheumatoid arthritis-specific autoantibodies to citrullinated fibrinogen Auger I Sebbag M Vincent C Balandraud N Guis S Nogueira L Svensson B Cantagrel A Serre G Roudier J Arthritis Rheum 2005 52 3424 3432 10.1002/art.21391 16255019 IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin Chapuy-Regaud S Nogueira L Clavel C Sebbag M Vincent C Serre G Clin Exp Immunol 2005 139 542 550 10.1111/j.1365-2249.2004.02708.x 15730401 The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin Masson-Bessiere C Sebbag M Girbal-Neuhauser E Nogueira L Vincent C Senshu T Serre G J Immunol 2001 166 4177 4184 11238669 A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis Berglin E Padyukov L Sundin U Hallmans G Stenlund H Van Venrooij WJ Klareskog L Dahlqvist SR Arthritis Res Ther 2004 6 R303 R308 464874 15225365 10.1186/ar1187 Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors Nielen MM van Schaardenburg D Reesink HW van de Stadt RJ van der Horst-Bruinsma IE de Koning MH Habibuw MR Vandenbroucke JP Dijkmans BA Arthritis Rheum 2004 50 380 386 10.1002/art.20018 14872479 Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study van Gaalen FA Linn-Rasker SP van Venrooij WJ de Jong BA Breedveld FC Verweij CL Toes RE Huizinga TW Arthritis Rheum 2004 50 709 715 10.1002/art.20044 15022309 How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis Visser H le Cessie S Vos K Breedveld FC Hazes JM Arthritis Rheum 2002 46 357 365 10.1002/art.10117 11840437 Prospect for an additional laboratory criterion for rheumatoid arthritis von Essen R Kurki P Isomaki H Okubo S Kautiainen H Aho K Scand J Rheumatol 1993 22 267 272 7505480 Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis Jansen AL van der Horst-Bruinsma I van Schaardenburg D van de Stadt RJ de Koning MH Dijkmans BA J Rheumatol 2002 29 2074 2076 12375314 The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis Kroot EJ de Jong BA van Leeuwen MA Swinkels H van den Hoogen FH van't Hof M van de Putte LB van Rijswijk MH van Venrooij WJ van Riel PL Arthritis Rheum 2000 43 1831 1835 10.1002/1529-0131(200008)43:8<1831::AID-ANR19>3.0.CO;2-6 10943873 Detection of antibodies to deiminated recombinant rat filaggrin by enzyme-linked immunosorbent assay: a highly effective test for the diagnosis of rheumatoid arthritis Vincent C Nogueira L Sebbag M Chapuy-Regaud S Arnaud M Letourneur O Rolland D Fournie B Cantagrel A Jolivet M Arthritis Rheum 2002 46 2051 2058 10.1002/art.10436 12209508 Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage Meyer O Labarre C Dougados M Goupille P Cantagrel A Dubois A Nicaise-Roland P Sibilia J Combe B Ann Rheum Dis 2003 62 120 126 1754441 12525380 10.1136/ard.62.2.120 Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis Paimela L Gripenberg M Kurki P Leirisalo-Repo M Ann Rheum Dis 1992 51 743 746 1004738 1377463 The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis van Jaarsveld CH ter Borg EJ Jacobs JW Schellekens GA Gmelig-Meyling FH van Booma-Frankfort C de Jong BA van Venrooij WJ Bijlsma JW Clin Exp Rheumatol 1999 17 689 697 10609067 Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis Vencovsky J Machacek S Sedova L Kafkova J Gatterova J Pesakova V Ruzickova S Ann Rheum Dis 2003 62 427 430 1754544 12695154 10.1136/ard.62.5.427 The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis van der Helm-van Mil AH Verpoort KN Breedveld FC Huizinga TW Toes RE de Vries RR Arthritis Rheum 2006 54 1117 1121 10.1002/art.21739 16572446 A review of the MHC genetics of rheumatoid arthritis Newton JL Harney SM Wordsworth BP Brown MA Genes Immun 2004 5 151 157 10.1038/sj.gene.6364045 14749714 The genetics revolution and the assault on rheumatoid arthritis Seldin MF Amos CI Ward R Gregersen PK Arthritis Rheum 1999 42 1071 1079 10.1002/1529-0131(199906)42:6<1071::AID-ANR1>3.0.CO;2-8 10366098 Mixed lymphocyte cultures in rheumatoid arthritis Stastny P J Clin Invest 1976 57 1148 1157 436767 1262462 The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis Gregersen PK Silver J Winchester RJ Arthritis Rheum 1987 30 1205 1213 10.1002/art.1780301102 2446635 Impact of shared epitope genotype and ethnicity on erosive disease: a meta-analysis of 3,240 rheumatoid arthritis patients Gorman JD Lum RF Chen JJ Suarez-Almazor ME Thomson G Criswell LA Arthritis Rheum 2004 50 400 412 10.1002/art.20006 14872482 Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influences the severity of rheumatoid arthritis van Gaalen FA van Aken J Huizinga TW Schreuder GM Breedveld FC Zanelli E van Venrooij WJ Verweij CL Toes RE de Vries RR Arthritis Rheum 2004 50 2113 2121 10.1002/art.20316 15248208 Detailed analysis of the variability of peptidylarginine deiminase type 4 in German patients with rheumatoid arthritis: a case–control study Hoppe B Haupl T Gruber R Kiesewetter H Burmester GR Salama A Dorner T Arthritis Res Ther 2006 8 R34 1526594 16469113 10.1186/ar1889 Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles Irigoyen P Lee AT Wener MH Li W Kern M Batliwalla F Lum RF Massarotti E Weisman M Bombardier C Arthritis Rheum 2005 52 3813 3818 10.1002/art.21419 16320316 Reshaping the shared epitope hypothesis: HLA-associated risk for rheumatoid arthritis is encoded by amino acid substitutions at positions 67–74 of the HLA-DRB1 molecule de Vries N Tijssen H van Riel PL van de Putte LB Arthritis Rheum 2002 46 921 928 10.1002/art.10210 11953968 Influence of shared epitope-negative HLA-DRB1 alleles on genetic susceptibility to rheumatoid arthritis Reviron D Perdriger A Toussirot E Wendling D Balandraud N Guis S Semana G Tiberghien P Mercier P Roudier J Arthritis Rheum 2001 44 535 540 10.1002/1529-0131(200103)44:3<535::AID-ANR101>3.0.CO;2-Z 11263767 New classification of HLA-DRB1 alleles supports the shared epitope hypothesis of rheumatoid arthritis susceptibility du Montcel ST Michou L Petit-Teixeira E Osorio J Lemaire I Lasbleiz S Pierlot C Quillet P Bardin T Prum B Arthritis Rheum 2005 52 1063 1068 10.1002/art.20989 15818663 A new classification of HLA-DRB1 alleles differentiates predisposing and protective alleles for rheumatoid arthritis structural severity Gourraud PA Boyer JF Barnetche T Abbal M Cambon-Thomsen A Cantagrel A Constantin A Arthritis Rheum 2006 54 593 599 10.1002/art.21630 16447236 Validation of the reshaped shared epitope HLA-DRB1 classification in rheumatoid arthritis Michou L Croiseau P Petit-Teixeira E du Montcel ST Lemaire I Pierlot C Osorio J Frigui W Lasbleiz S Quillet P Arthritis Res Ther 2006 8 R79 1526640 16646982 10.1186/ar1949 The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis Arnett FC Edworthy SM Bloch DA McShane DJ Fries JF Cooper NS Healey LA Kaplan SR Liang MH Luthra HS Arthritis Rheum 1988 31 315 324 10.1002/art.1780310302 3358796 HLA class II association with rheumatoid arthritis: facts and interpretations Zanelli E Breedveld FC de Vries RR Hum Immunol 2000 61 1254 1261 10.1016/S0198-8859(00)00185-3 11163080 Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP) Forslind K Ahlmen M Eberhardt K Hafstrom I Svensson B Ann Rheum Dis 2004 63 1090 1095 10.1136/ard.2003.014233 15308518 Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins Huizinga TW Amos CI van der Helm-van Mil AH Chen W van Gaalen FA Jawaheer D Schreuder GM Wener M Breedveld FC Ahmad N Arthritis Rheum 2005 52 3433 3438 10.1002/art.21385 16255021 Association of rheumatoid factors and anti-filaggrin antibodies with severity of erosions in rheumatoid arthritis Bas S Perneger TV Mikhnevitch E Seitz M Tiercy JM Roux-Lombard P Guerne PA Rheumatology (Oxford) 2000 39 1082 1088 10.1093/rheumatology/39.10.1082 11035127 Prevalence of antikeratin antibodies in Greek patients with rheumatoid arthritis. A clinical, serologic, and immunogenetic study Boki KA Kurki P Holthofer H Tzioufas AG Drosos AA Moutsopoulos HM J Rheumatol 1995 22 2046 2048 8596142 Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset Goldbach-Mansky R Lee J McCoy A Hoxworth J Yarboro C Smolen JS Steiner G Rosen A Zhang C Menard HA Arthritis Res 2000 2 236 243 17811 11056669 10.1186/ar93 Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis Verpoort KN van Gaalen FA van der Helm-van Mil AH Schreuder GM Breedveld FC Huizinga TW de Vries RR Toes RE Arthritis Rheum 2005 52 3058 3062 10.1002/art.21302 16200610 Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule Hill JA Southwood S Sette A Jevnikar AM Bell DA Cairns E J Immunol 2003 171 538 541 12847215